Chiltern and EPS International Hold a Joint Seminar in Tokyo, Japan

LONDON and TOKYO - Chiltern International Limited (Chiltern), a global Clinical Research
Organization (CRO) that provides clinical development and staffing services
in Europe, the Americas and India and its Asian partner EPS International Co.
Ltd. (EPS INTERNATIONAL), a wholly owned subsidiary of EPS Co. Ltd., a
leading provider of clinical development services in the Asian region, have
jointly organized a seminar in Tokyo, Japan on 24th April 2009 to coincide
with the 3rd anniversary of EPS International.

“We are very pleased to be part of the anniversary celebration of our
partner EPS INTERNATIONAL in Japan,” said Glenn Kerkhof, CEO of Chiltern.
“With global consolidation in the pharma sphere, Asia is becoming an
increasingly attractive market for clinical trial services. The Chiltern/EPS
INTERNATIONAL partnership has been beneficial to both partners and helped
continue to focus on the joint mission to deliver expert, high quality,
clinical development services around the world.”

“We are pleased to hold this seminar together with Chiltern
International, a quality reputable global CRO having headquarters in the UK,”
said Tatsuhiko Ichiki, President & CEO of EPS INTERNATIONAL. “Through this
seminar, it shows our commitment and expectation in this strategic
collaboration enabling EPS INTERNATIONAL to expand geographical reach and
attain global standard capability to best support our clients in the global
drug development programs.”

Chiltern provides services to EPS INTERNATIONAL from their network of
offices throughout Europe, the Americas and India. Similarly, EPS
INTERNATIONAL provides clinical development services for the Asian region
from their offices in Japan, China, Singapore, Korea and Taiwan.

Company profile

About Chiltern:

Established in 1982, Chiltern is a leading global Contract Research
Organization with extensive experience conducting and staffing international
Phase I to Phase IV clinical trials across a broad range of therapeutic areas
for a wide variety of clients. Chiltern has conducted trials in more than 40
countries and employs 1400 staff across 27 countries. Chiltern provides
services including Early Phase, Global Clinical Development, Late Phase,
Biometrics, Medical and Regulatory Affairs and Resourcing Solutions. Further
information is available at www.chiltern.com.

About EPS International:

EPS International Co. Ltd., a wholly owned subsidiary of a public listed
company, EPS Co. Ltd. in Tokyo, Japan, commenced its business operations in
April 2007. EPS INTERNATIONAL aims to provide a seamless clinical research
and development platform through strategizing and synergizing its established
research networks, valuable knowledge, know-how, resources and experiences in
Asia region. EPS INTERNATIONAL is fully supported by a team of high caliber,
diligent and dedicated clinical professionals having many years of
experiences in managing large- and small-scale, global and local clinical
trials covering from first-in-man to post marketing surveillance for new
chemical entities, biologics and medical devices.

For More Information Contact:

Mac McElroy Stuart McGuire
Chiltern International, Inc. Chiltern International Ltd.
1241 Volunteer Parkway 171 Bath Road
Suite 950 Slough
Bristol, TN 37620 Berkshire SL1 4AA
USA UNITED KINGDOM
Tel: +1-423-968-9533 Tel: +44-(0)-1753-512-000
Fax: +1-423-968-3567 Fax: +44-(0)-1753-511-116
Email: mac.mcelroy@chiltern.com Email: stuart.mcguire@chiltern.com

Source: Chiltern

Mac McElroy, +1-423-968-9533, or fax, +1-423-968-3567, mac.mcelroy at chiltern.com; or Stuart McGuire, +44-(0)1753-512-000, or fax, +44-(0)1753-511-116, stuart.mcguire at chiltern.com, both of Chiltern